Potent, reversible AMP-activated protein kinase (AMPK) activator (EC50
= 0.8 μ
M) that displays selectivity towards β
1 subunit-containing heterotrimers. Inhibits fatty acid synthesis (IC50
= 3.2 μ
M) and decreases plasma glucose and triglyceride levels in vivo
. Also inhibits proliferation of mesenchymal stem cells, and impedes reprogramming of mouse embryonic fibroblasts to iPSCs.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Activation of AMP-activated protein kinase (AMPK) provides a metabolic barrier to reprogramming somatic cells into stem cells.
Vazquez-Martin et al.
Cell Cycle, 2012;5:974
Defining the mechanism of activation of AMP-activated protein kinase by the small molecule A-769662, a member of the thienopyridone family.
Sanders et al.
Thienopyridone drugs are selective activators of AMP-activated protein kinase β1-containing complexes.
Scott et al.
Role of AMP-activated protein kinase in regulating hypoxic survival and proliferation of mesenchymal stem cells.
de Meester et al.
Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome.
Cool et al.
Cell Met., 2006;3:403
Metformin activates a duodenal Ampk-dependent pathway to lower hepatic glucose production in rats.
Duca et al.
The citations listed below are publications that use Tocris products. Selected citations for A 769662 include:
Showing Results 1 - 10 of 15